How to appeal a UnitedHealthcare genetic testing denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for genetic testing

Cited policy: UHC Genetic Testing for Hereditary Cancer Susceptibility Syndromes (Optum Genetic Testing Solution)

NCCN-aligned for hereditary cancer; documented family/personal hx meeting NCCN HBOC, Lynch, Li-Fraumeni, Cowden criteria; pre-test counseling.

How UnitedHealthcare denies genetic testing — and how to counter it

Where UnitedHealthcare pushes back: 1) 'Member does not meet NCCN criteria for testing'; 2) 'Multi-gene panel not medically necessary; only single-gene (BRCA1/2) covered'; 3) WES/WGS experimental outside neonatal/pediatric undiagnosed; 4) 'NIPT not covered for average-risk singleton pregnancy' (older); 5) 'Tumor genomic profiling experimental for non-NSCLC tumors'.

Counter-arguments that hold up: Cite specific NCCN BOP-X criterion met (e.g., breast ca <=45 = automatic indication, BOP-2). USPSTF 2019 Grade B BRCA + ACA §2713 — counseling/testing covered without cost-sharing for at-risk women (45 CFR §147.130). ACOG #226 (2020) — cfDNA offered to all pregnant patients; UHC updated NIPT policy 2022. NCCN BOP/COL footnotes endorse multi-gene panels when >1 syndrome on differential. CMS NCD 90.2 covers FDA-approved CDx in advanced cancer.

What UnitedHealthcare typically denies for genetic testing

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For genetic testing, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the genetic testing treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Hereditary cancer panel
• BRCA1/2
• Lynch panel
• Cardiogenetic
• WES / WGS
• Carrier screening

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.